Phase III data show Novartis investigational bronchodilator QAB149 significantly improves lung function over current treatments in COPD[1],[2]
Links shared publicly online about this topic.
- 2,028total visits
Phase III data show Novartis investigational bronchodilator QAB149 significantly improves lung function over current treatments in COPD[1],[2]
Basel, May 21, 2009 - Initial results from three pivotal phase III trials show the Novartis investigational bronchodilator QAB149 (indacaterol) could deliver clinically relevant* lung function improvements, within five minutes of the first dose, lasting for 24 hours in patients with chronic obstructive pulmonary disease (COPD)[3],[4],[5].
View full resource at novartis.com
Tags: Lung, COPD, Disease and Condition, Novartis, Pulmonology
Most Recently Shared on May 21, 2009 at 5:37 am By:
Phase III data show Novartis investigational bronchodilator QAB149 significantly improves lung function over cur.. http://twurl.nl/456hie
Advertisement
